---
title: "Lipid Nanoparticles for Acute Myeloid Leukemia Immunotherapy: Potential and Challenges"
id: "frontiers-in-immunology-15-the-transformative-potential-of-lipid-nanoparticles-tailored-for-acute-myeloid"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-the-transformative-potential-of-lipid-nanoparticles-tailored-for-acute-myeloid"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1799525"
published_at: "2026-09-07T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Lipid Nanoparticles for Acute Myeloid Leukemia Immunotherapy: Potential and Challenges
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-the-transformative-potential-of-lipid-nanoparticles-tailored-for-acute-myeloid
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1799525)
- **Published At:** 2026-09-07T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The source is a review article listed in Frontiers in Immunology addressing **lipid nanoparticles** tailored for **acute myeloid leukemia** (**AML**) **immunotherapy**. - The accessible content in the provided source consists primarily of site navigation, journal sections, and header metadata; the full review text and substantive article details were not present. - No experimental results, preclinical or clinical data, study methods, or author conclusions were available in the provided source material. - Important specifics such as nanoparticle composition, targeting strategies, payload types, immunologic mechanisms, safety findings, or clinical translation steps were not reported in the retrieved content. - Because the article body was not included, concrete claims about efficacy, trial phases, or comparative performance versus other delivery platforms cannot be summarized. - The article is identified as a REVIEW in Frontiers in Immunology, but bibliographic details beyond that label were incomplete in the provided extract. - The absence of the article body prevents extraction of actionable recommendations, research gaps, or prioritized next steps from the original authors. - Users seeking detailed, source-author statements about **AML immunotherapy** using **lipid nanoparticles** will need the complete article; this rewrite summarizes only the metadata and the lack of accessible content.
## Clinical Analysis & Structured Key Points
Frontiers | The transformative potential of lipid nanoparticles tailored for acute myeloid leukemia immunotherapy REVIEW article Front. Immunol. , 07 September 2026 Sec. T Cell Biology Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1799525 Published in Frontiers in Immunology T Cell Biology 7 impact factor 11.3 citescore Part of a Research Topic Evolving Therapeutic Landscape of Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapies 24k views 6 articles Editor & Reviewers Edited by S P Sid P Kerkar Reviewed by M S Md Sadique Hussain J I Jorge Ibanez-Vega Outline Figures and Tables Figure 1 View in article Figure 2 View in article Table 1 Tmod AML design rationale. View in article Table 2 Summary of clinical trials of CAR-Ts or TCEs for AML. View in article REVIEW article Front. Immunol. , 07 September 2026 Sec. T Cell Biology Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1799525 The transformative potential of lipid nanoparticles tailored for acute myeloid leukemia immunotherapy A K Alexander Kamb 1 * J S John S. Welch 2 1. Discovery Research, A2 Biotherapeutics, Agoura Hills, CA, United States 2. Clinical Development, A2 Biotherapeutics, Agoura Hills, CA, United States Article metrics View details Abstract T-cell engagers and engineered cell therapies have yet to deliver the same spectacular results in acute myeloid leukemia (AML) that they have in other hematologic malignancies. In this review, we analyze the challenges with AML immunotherapy development, including on-target, off-tumor toxicity, cytokine release syndrome (CRS), and the “myeloid sink.” We then discuss the emergence of two technologies that could address the major challenges with investigational AML therapeutics: targeted, lipid nanoparticles (LNPs) loaded with specific mRNAs and a type of synthetic logic gate (a NOT gate). This approach builds on recent advancements of mRNA-loaded LNPs that developed with the COVID19 vaccines and evolved into vehicles for delivery to T cells. The LNP modality offers a new opportunity for effective treatment of patients with AML. 1 Introduction Acute myeloid leukemia (AML) is a common blood cancer of the elderly, with a median age at diagnosis of 68; approximately 11,000 people in the United States and over 130,000 people worldwide die of AML annually ( 1 ). AML originates from the early progenitors of the myeloid hematopoietic lineage and encompasses a variety of forms ranging from partially differentiated cells that resemble monocytes to poorly differentiated blasts ( 2 ). Outside of two molecularly defined subtypes (M3-acute promyelocytic leukemia with 15;17 translocation and perhaps NPM1/IDH co-mutant AML), stem cell transplant (SCT) remains the only modality with long-term responses consistent with cure. Only half of patients with AML in the US qualify for SCT, and roughly half of these transplant recipients ultimately relapse. The therapeutic options for those too old or otherwise unqualified for transplant are largely ineffective, with a 5-year survival of about 10%. Such poor outcomes occur not because we lack a sophisticated understanding of the molecular basis of AML ( 3 ); rather, the dismal survival rates result from known factors that challenge drug discoverers and clinicians ( 4 ; see next section). Indeed, the challenges of investigational medicines in AML have compelled many drug discovery organizations to abandon investment in novel therapies. In contrast, oncologists specialized in other blood cancer types, notably non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), choose from an increasing menu of therapeutic options, including highly effective new modalities such as T-cell engagers (TCEs) and cell therapy ( 5 , 6 ; see 7 for a review of AML cell therapy). So why is AML a particularly difficult blood cancer to treat? Translational studies over recent years exposed many of the reasons that investigational medicines have failed ( Table 1 ). In the following sections, we review the causes for the failures of AML immunotherapies and describe how integration of two relatively new therapeutic technologies, synthetic logic gates and mRNA-loaded lipid nanoparticles (LNPs), provides a plausible solution to each of these obstacles. Although there is not yet direct evidence for the combination of these modalities (LNPs and logic gates) in AML, we argue that together they offer several conceptual advantages and are worth investigating. Table 1 Challenges for AML immunotherapy Causes AML tLNP mitigations On-target, off-tumor toxicity Overlap between antigens on tumor and normal cells. No new antigens to find. New ways of using known antigens. Tmod NOT gate blocker to protect HSCs, etc. Cytokine release syndrome Overactivation of T cells. Tumor lysis syndrome. Overactivation/stimulation by and of normal myeloid cells. Blocker(s) to protect normal cells. Graded intra-patient dose escalation. mRNA LNPs to limit duration. CD8-targeted LNPs. Chemotherapy and lymphodepletion toxicity Need for tumor induction. Need for engraftment (SCT and CAR-T). T cells engineered in situ with LNPs. Limited potency Dose-limiting toxicity limits dosing and boosters. T-cell exhaustion by high tumor burden. Low number/quality of patient T cells. Minimization of CRS. Minimization of killing of normal cells. Re-dose LNPs. Higher quality of T cells modified in situ . Antigen escape Heterogeneity of AML. Selective pressure for resistance to therapy. Choose antigens for maximum efficacy. Combine antigens. Hostile tumor microenvironment Cellular/biochemical factors that impede inflammatory process. Factors that affect tumor cell survival. Re-dose LNPs. Add boosters that enhance cytotoxicity. Tmod AML design rationale. Tmod targeted LNPs address the problems that have stymied immunotherapy for AML. AML, acute myeloid leukemia; CAR-T, chimeric antigen receptor T cell; CD8, cluster of differentiation 8 (referring to CD8+ cytotoxic T cells); CRS, cytokine release syndrome; HSC(s), hematopoietic stem cell(s); LD, lymphodepletion; LNP(s), lipid nanoparticle(s); SCT, stem cell transplant; tLNP, targeted lipid nanoparticle. 2 The challenges of AML immunotherapy 2.1 On-target, off-tumor toxicity A major obstacle of new cancer treatments is the rarity of truly tumor-specific targets for the “magic bullets” that have been sought intensely since they were envisioned by Paul Ehrlich in 1908 ( 8 ). Although a few such cancer targets have been found (e.g., BCR-ABL in chronic myeloid leukemia), these are rare and/or impractical to exploit therapeutically. Despite the notable success of immunotherapeutics in both NHL and MM, the targeted antigens are not uniquely expressed on tumor cells (e.g., CD19, CD20, CD38, and BCMA). Rather, these antigens are specific to B-cell lineages and mark both malignant and normal cells for destruction. The key to therapeutic success is not tumor-specificity of antigens, but rather the fact that patients can survive for months without B cells. Because AML cells are closely related to essential cell types, such as neutrophils and hematopoietic stem cells (HSCs), immunologic targeting of cells expressing AML antigens can result in myeloid cytopenias and even aplasia. Whereas prolonged B-cell cytopenia can be manageable, neutropenia lasting more than 4–6 weeks can lead to life-threatening fungal and bacterial infections. Several antigens have been identified that have varying degrees of AML specificity and homogeneity of expression within AML tumors. These antigens include CD33, FLT3, CLL-1 (CLEC12A), and CD123 (IL3RA). Immunotherapeutics targeting each of these have been studied in clinical trials with mixed success ( Table 2 ). The details vary from study to study, but consistent patterns of toxicity and limited efficacy have been observed, as described below. Table 2 Study institution) Modality Indication [no. patients treated] LD Doses received [no. patients in dose group] Safety [no. patients with event] Efficacy [no. patients with event] Comments Target: CD33 NCT05105152 Appelbaum et al, 2024 (Fred Hutch) ( 9 ) SC-DARIC33, fully human, rapamycin-regulated CD33-directed CAR-T pediatric and young adult patients with R/R AML [3] flu/cy (doses undisclosed) SC-DARIC33: 1×10 6 cells/kg with rapamycin 0.5 mg/m 2 daily oral dose on Days 3–21 [3] markers associated with CAR-T-cell activation and potential CRS early signs of antitumor impact: chloroma necrosis [1] 99.8% reduction in circulating blast-like CD33-high cells [1] preclinical data demonstrated the DARIC33 T cell function paused when rapamycin was withdrawn and restored with rapamycin re-exposure NCT01864902 Wang et al, 2015 (Chinese PLA General Hospital) ( 10 ) autologous CD33-directed CAR-T R/R AML and long-term pancytopenia [1] none a total of 1.12×10 9 cells (over 4 doses across 4 days) [1] CRS [1] grade 4, exacerbation of pre-existing pancytopenia [1] no responses; bone marrow blast reduction NCT05984199 Shah et al, 2024 and Mushtaq et al, 2026 (Vor Bio) ( 11 , 12 ) VCAR33, donor-derived CD33-directed CAR-T adults with relapsed or MRD+ CD33+ AML who had HLA-matched allogeneic HCT [15] flu 120 mg/m 2 cy 1000 mg/m 2 Arm A (bone marrow blasts ≥5%): DL1: 1×10 6 /cells/kg [7] Arm B (bone marrow blasts 10-fold decrease in leukemic stem cells designed with an inhibitory NOT gate CAR for endomucin to selectively spare healthy hematopoietic stem/progenitor cells Summary of clinical trials of CAR-Ts or TCEs for AML. AACR, American Association for Cancer Research; AML, acute myeloid leukemia; BPDCN, blastic plasmacytoid dendritic cell neoplasm; CAR-T, chimeric antigen receptor T cell; CLL-1, C-type lectin-like molecule-1; CMML, chronic myelomonocytic leukemia; CR, complete response or complete remission; CRh, complete remission with partial hematologic recovery; CRi, complete remission with incomplete hematologic recovery; CRS, cytokine release syndrome; DLT, dose-limiting toxicity; FLT3(L), FMS-like tyrosine kinase 3(ligand); flu/cy, fludarabine and cyclophosphamide; GGT, gamma-glutamyl transferase; GVHD, graft-versus-host disease; HSC(s), hematopoietic stem cell(s); HCT, hematopoietic cell transplantation; ICANS, immune effector cell-associated neurotoxicity syndrome; IRR, infusion-related reactions; IV, intravenous; LD, lymphodepletion; mem-IL-15, membrane-bound interleukin 15; MDS, myelodysplastic syndrome; MLFS, morphologic leukemia-free state; MRD (–)/MRD(+), measurable (or minimal) residual disease negative/positive; NK, natural killer; OR, objective response; PIF/ER, primary induction failure/early relapse; PR, partial response; R/R, relapsed/refractory; RP2D, recommended phase 2 dose; SC, subcutaneous; SCT, stem cell transplant; TCE, T-cell engager; TME, tumor microenvironment. Clinical data from clinical trials of CAR-Ts or TCEs for AML suggest all targets have toxicity risk. It is difficult in most cases to disentangle the effects of preconditioning lymphodepletion from the cell therapy product. [For a systematic review of CAR-T therapy for AML, see ( 7 )]. 2.2 Cytokine release syndrome A common type of toxicity observed with the more potent types of immunotherapeutics (i.e., TCEs and chimeric antigen receptor T cells [CAR-Ts]) is CRS, a form of systemic inflammation characterized by immune cell activation, proliferation, and high levels of blood cytokines ( 26 ). Although not exclusive to AML therapy, CRS has been especially problematic in AML and often hampers dosing, or worse, can manifest with such severity that it causes trial termination and even patient deaths ( 27 ). Although the mechanism of CRS is not fully understood, certain aspects are clear: CRS only occurs in the presence of antigen and is therefore considered a form of on-target toxicity that does not directly cause destruction of healthy tissues ( 28 ); rather, it can induce a wind-up of immune activation with non-specific neurologic symptoms called immune effector cell-associated neurotoxicity syndrome (ICANS) or engulfment by macrophages in the liver, spleen, bone marrow, and lymph nodes, described initially as hemophagocytic lymphohistiocytosis (HLH) and more recently as immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) ( 29 ). Both of these extreme forms of CRS are rare but can be a fatal consequence of CAR-T treatment. All antigens tested in AML so far (CD33, FLT3, CLL-1, and CD123) seem to induce CRS when targeted by T cells in at least some trials, suggesting it is not specific to one antigen type (see Table 2 ). CRS responds to glucocorticoids and IL-6 antagonist antibodies ( 26 ), but these immune-system-dampening remedies may impact immunotherapy efficacy. At least for immunotherapy of B-cell malignancies, CRS generally is dose-dependent and more pronounced in patients with heavy tumor burden ( 30 ). CRS has been observed in clinical studies and toxicology studies in primates at high doses of CAR-Ts where tumors are not present ( 31 – 33 ). Thus, expression of antigen on healthy tissues is sufficient to trigger CRS. With TCEs like blinatumomab, mosunetuzumab-axgb, and flotetuzumab, CRS can be reduced by gradual ramping up the infusion dose, suggesting the kinetics of exposure are important ( 26 ). The T cells that initiate the process may desensitize and/or traffic out of the blood where they are less likely to encounter additional TCE molecules. The magnitude and manifestation of CRS likely depend on the tumor type targeted by the T cells ( 26 ). In AML, the origin of the hyper-inflammatory cycle is not established. Although it likely begins with antigen-dependent activation of T cells, it is not certain if inflammation escalates because of: The scale of direct T-cell activation by the antigen. The release of cytokine granules from the targeted tumor cells that can be numerous in some patients; and/or The on-target, off-tumor killing of normal myeloid cells. Although cell therapies using non-T-cell effectors (e.g., natural killer [NK] cells) target the same antigens, they induce lower cytokine levels, suggesting that T-cell overactivation primarily drives this escalating inflammation ( 24 ). CRS may be a property of T cells that correlates with their potency as cytotoxic effectors. 2.3 Complications from chemotherapy and lymphodepletion AML is treated by induction with chemotherapeutics to reduce tumor burden and, in the case of SCT, to eliminate the host immune system in preparation for engraftment. Although necessary—at least for SCT—LD is a substantial toxicity burden on patients that increases risk of infection. In addition, common LD chemotherapies (e.g., fludarabine and cyclophosphamide) are active in AML, creating a confounding variable in the interpretation of clinical results that clouds conclusions about the role of the investigational therapeutic in efficacy and toxicity. For example, after treatment with CAR-Ts, patients with AML often display marrow aplasia/hypocellularity. Is this the result of LD, on-target elimination of bone marrow cells, or HLH? Does exposure to LD before CAR-T induce additional susc
## Related Clinical Research

- [TIGIT-CD155 interaction modulates adapter CAR-T cell function in AML — knockout screen findings](https://medichelpline.com/clinical-feed/pubmed-42750591.md) (DOI: 10.1080/2162402X.2026.2717853)
- [Childbirth Rates Among Female Cancer Survivors in Taiwan: Nationwide Population Study](https://medichelpline.com/clinical-feed/plos-one-0-rates-of-childbirth-in-female-cancer-survivors-a-population-based-study-in.md)
- [One-month physicochemical stability of idarubicin diluted in polyolefin (Freeflex) infusion bags](https://medichelpline.com/clinical-feed/plos-one-21-one-month-physicochemical-stability-study-of-idarubicin-prepared-in-polyolefin.md)
- [Inferring tumor kinetics from single routine H&E biopsies to run virtual radiotherapy trials](https://medichelpline.com/clinical-feed/medrxiv-9-effective-tumor-kinetics-inferred-from-single-routine-h-e-biopsies-enable.md)
- [EuroNet-PHL-LP1 Trial: Complete Resection Versus Low-Dose Chemotherapy for Pediatric Low-Risk NLPHL](https://medichelpline.com/clinical-feed/pubmed-42234940.md) (DOI: 10.1182/bloodadvances.2026019765)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.